AZTR — Azitra, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1701478 ·
Last close
$0.13
Market Cap
$8.00M
52W High
$1.09
52W Low
$0.10
ADV30
759,359
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,419,168 | -3,347,660 | 8,916,046 | 6,727,810 | 1,581,707 |
| Mar 2026 | 0 | — | -3,933,924 | -3,927,240 | 12,126,804 | 10,051,003 | 1,646,521 |
| Dec 2025 | 0 | — | -2,226,591 | -2,233,504 | 5,025,386 | 2,068,083 | 1,224,156 |
| Sep 2025 | 0 | — | -2,768,484 | -2,764,528 | 4,300,279 | 1,401,878 | 2,021,103 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,629,668
Investing CF
$-198,362
Financing CF
$17,672,322
CapEx
$-198,362
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.67
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,448,436
Inventory
—
Receivables
$154,492
ST Investments
—
EBIT TTM
$-11,796,241
Pretax Income TTM
$-11,805,946
Interest Exp TTM
$9,705
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,966,665 | -10,955,370 | 5,025,386 | 1,224,156 | 3,801,230 | -11,224,125 |
| Dec 2024 | 7,500 | -10,985,140 | -8,967,492 | 7,358,802 | 1,660,504 | 5,698,298 | -10,183,740 |
| Dec 2023 | 686,000 | -7,450,546 | -11,283,781 | 5,115,486 | 2,202,340 | 2,913,146 | -7,362,375 |
| Dec 2022 | 284,000 | -9,453,604 | -10,680,366 | 7,167,443 | 43,427,753 | -36,260,310 | -8,349,469 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-11,814,265
OpCashFlow TTM
—
Assets (Latest)
$12,126,804
Forward EPS
$-0.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CNSP | CNS Pharmaceuticals, Inc. | $7.82M | $5.35 | — |
| MBRX | Moleculin Biotech, Inc. | $8.26M | $0.42 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $8.32M | $5.51 | — |
| SNGX | SOLIGENIX, INC. | $7.54M | $0.35 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.46M | $4.76 | — |
News headlines (Yahoo Finance, 1h cache)
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
2026-09-28 09:32 · Yahoo
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
/C O R R E C T I O N -- Azitra, Inc./
2026-07-15 15:33 · Yahoo
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
2026-07-15 14:10 · Yahoo
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
2026-06-17 12:00 · Yahoo
Azitra, Inc. to Present at 2026 BIO International Convention
2026-06-16 21:28 · Yahoo
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
2026-06-04 20:05 · Yahoo
AZTR: More Background on Cosmetic Opportunity
2026-05-22 11:15 · Yahoo
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
2026-05-13 12:30 · Yahoo
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
2026-05-06 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.